Physician profile
Ronald Banaag Villanueva
NPI 1508838434
$217,003.15
in general payments reported to CMS, 2019-2025
65 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $37K · 2021: $42K · 2022: $24K · 2023: $6,357 · 2024: $32K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $14K · Travel and Lodging: $1,224 · Honoraria: $300 · Education: $53.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,587.50 |
| Food and Beverage | $13,740.41 |
| Travel and Lodging | $1,223.56 |
| Honoraria | $300.00 |
| Education | $53.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $105,089.41 | 2019-2025 | Farxiga, Lokelma |
| Lilly USA, LLC | $43,477.30 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $32,258.54 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,690.13 | 2019-2025 | Jardiance |
| Abbvie INC. | $5,499.37 | 2019-2025 | Ubrelvy, Qulipta, Synthroid |
| Novo Nordisk INC | $3,586.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amneal Pharmaceuticals LLC | $1,494.30 | 2019-2025 | Unithroid |
| Dexcom, INC. | $1,258.66 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $830.46 | 2019-2025 | Korlym |
| Abbott Laboratories | $807.01 | 2019-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $745.36 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Inpen Smart Insulin Delivery System |
| Bayer Healthcare Pharmaceuticals INC. | $690.58 | 2021-2025 | |
| Ascensia Diabetes Care US INC. | $549.40 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $538.37 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $524.91 | 2019-2025 | Afrezza |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $446.42 | 2024-2025 | Mycapssa, Myalept |
| Intuity Medical INC | $422.41 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Insulet Corporation | $358.56 | 2019-2025 | Omnipod |
| Amgen INC. | $301.83 | 2019-2025 | Tepezza, Evenity |
| Pfizer INC. | $264.69 | 2020-2025 | |
| Antares Pharma, INC. | $251.97 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Xeris Pharmaceuticals, INC. | $238.46 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $196.94 | 2020-2025 | |
| Madrigal Pharmaceuticals | $164.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Opko Pharmaceuticals, LLC | $164.32 | 2022-2024 | Rayaldee |
| Cequr Corporation | $147.41 | 2023-2025 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $145.28 | 2019-2025 | Strensiq |
| Horizon Therapeutics Plc | $141.39 | 2022 | |
| Merck Sharp & Dohme LLC | $130.02 | 2019-2021 | |
| Esperion Therapeutics, INC. | $128.23 | 2024-2025 | Nexletol |
| Medtronic Minimed, INC. | $128.08 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $127.67 | 2019-2021 | |
| Ibsa Pharma INC. | $98.88 | 2019-2025 | Tirosint, Licart, Flector |
| Amarin Pharma, INC. | $93.89 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $71.67 | 2025 | Yorvipath |
| Genzyme Corporation | $71.00 | 2020 | |
| Verity Pharmaceuticals INC. | $67.46 | 2024-2025 | Tlando, Trelstar |
| Eisai INC. | $64.36 | 2019 | |
| Kyowa Kirin, INC. | $63.46 | 2023-2024 | Crysvita |
| Clarus Therapeutics INC. | $56.91 | 2021 | |
| Becton, Dickinson and Company | $56.02 | 2020-2022 | |
| Vivus LLC | $55.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.68 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $46.46 | 2019-2020 | |
| Aytu Biopharma, INC. | $38.76 | 2019 | |
| Recordati_rare_diseases_inc. | $33.59 | 2021-2023 | Isturisa, Signifor Lar |
| Beta Bionics, INC. | $25.60 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Lifescan, INC. | $24.21 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $24.19 | 2020 | |
| Rgh Enterprises LLC | $22.59 | 2025 | |
| Halozyme INC | $22.16 | 2023 | |
| Sequel Med Tech, LLC | $20.88 | 2025 | Twiist |
| Soleno Therapeutics, INC. | $17.62 | 2025 | Vykat Xr |
| Nalpropion Pharmaceuticals LLC | $17.06 | 2019 | |
| Amryt Pharma Holdings Ltd | $16.65 | 2022 | |
| Companion Medical, INC. | $16.56 | 2019 | |
| Intra-Sana Laboratories | $16.16 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Rhythm Pharmaceuticals, INC. | $15.47 | 2022 | |
| Valeritas, INC. | $15.39 | 2019 | |
| Endo Pharmaceuticals INC. | $14.84 | 2021 | |
| Almatica Pharma LLC | $14.44 | 2025 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $13.58 | 2021 | |
| Acella Pharmaceuticals, LLC | $13.48 | 2024 | NP Thyroid 60 |
| Shire North American Group INC | $12.02 | 2019 | |
| Senseonics, Incorporated | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Villanueva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.